Biogen Inc. (NASDAQ: BIIB) was trading in a muted range on Friday, May 22, as the company continued to manage investor expectations around the commercial trajectory of Leqembi, its Alzheimer’s drug.
Leqembi, developed in partnership with Eisai, received full FDA approval in July 2023 and was widely expected to become a blockbuster treatment for early Alzheimer’s disease.
The commercial ramp has been slower than many had anticipated, with challenges around patient identification, diagnostic infrastructure, and insurance reimbursement limiting near-term uptake.
Biogen has been working with healthcare systems and insurance providers to broaden access, and the company has signalled that it expects uptake to accelerate as the infrastructure around amyloid testing and infusion administration matures.
The stock has had a difficult period in 2025 and 2026, trading well below the peaks reached when Alzheimer’s drug approvals first generated investor excitement.
Biogen’s other legacy products, including Tecfidera for multiple sclerosis and Spinraza for spinal muscular atrophy, continue to generate revenue, though they face generic and biosimilar competition.
The company has restructured its research pipeline to focus on neuroscience and rare diseases, areas where Biogen believes it has a sustained competitive advantage.
Analyst sentiment on BIIB is mixed, with some viewing the current price as an attractive entry point if Leqembi adoption begins to inflect upward in the second half of 2026.
The stock is included in NASDAQ healthcare and biotech indices and attracts institutional coverage from both speciality healthcare funds and generalist technology-focused investors.
Biogen’s next major catalyst will be updated Leqembi sales data in its upcoming quarterly earnings report, which will be closely scrutinised for evidence of inflection in adoption rates.
